Multipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
AssigneesABT Holding Company, Regents of the University of Minnesota
InventorsLeo T Furcht, catherine M Verfaillie, Morayma Reyes
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.
Claims101
An isolated multipotent adult stem cell (MASC), wherein the cell has the capacity to be induced to differentiate to form at least one differentiated cell type of mesodermal, ectodermal and endodermal origin.
A composition comprising a population of MASC and a culture medium, wherein the culture medium expands the MASC.
A composition comprising a population of fully or partially purified MASC progeny.
A method of treatment comprising administering to a patient in need thereof a therapeutically effective amount of MASC or their progeny.
A therapeutic composition comprising MASC and a pharmaceutically acceptable carrier, wherein the MASC are present in an amount effective to produce tissue selected from the group consisting of bone marrow, blood, spleen, liver, lung, intestinal tract, eye, brain, immune system, bone, connective tissue, muscle, heart, blood vessels, pancreas, central nervous system, kidney, bladder, skin, epithelial appendages, breast-mammary glands, fat tissue, and mucosal surfaces including oral esophageal, vaginal and anal.
A therapeutic method for restoring organ, tissue or cellular function to a patient in need thereof comprising the steps of:
- (a) removing MASC from a mammalian donor;
- (b) expanding MASC to form an expanded population of undifferentiatied cells;
- and
- (c) adminstering the expanded cells to the patient, wherein organ, tissue or cellular function is restored.
A method of inhibiting the rejection of a heterologous MASC transplanted into a patient comprising the steps of:
- (a) introducing into the MASC, ex vivo, a nucleic acid sequence encoding the recipient's MHC antigens operably linked to a promotor, wherein the MHC antigens are expressed by the MASC;
- and
- (b) transplanting the MASC into the patient, wherein MHC antigens are expressed at a level sufficient to inhibit the rejection of the transplanted MASC.
A method of inhibiting the rejection of a heterologous MASC transplanted into a patient comprising the steps of:
- (a) transgenically knocking out expression of MHC antigens in the MASC;
- and
- (b) transplanting the transgenic MASC into the patient, wherein said MHC antigens are not expressed by the MASC such that rejection of the transplanted MASC is inhibited.
A method of generating blood or individual blood components ex vivo comprising the steps of:
- (a) isolating MASC;
- and
- (b) differentiating the MASC to form blood or blood components.
A method of drug discovery comprising the steps of:
- (a) analyzing the genomic or proteomic makeup of MASC or their progeny;
- (b) employing analysis thereof via bioinformatics and/or computer analysis using algorithms;
- and
- (c) assembling and comparing new data with known databases to discover new drugs.
A method of identifying the components of a differentiation pathway comprising the steps of:
- (a) analyzing the genomic or proteomic makeup of MASC;
- (b) inducing differentiation of MASC;
- (c) analyzing the genomic or proteomic makeup of intermediary cells in the differentiation pathway;
- (d) analyzing the genomic or proteomic makeup of terminally differentiated cells in the differentiation pathway;
- (e) using bioinformatics and/or algorithms to characterize the genomic or proteomic makeup of MASC and their progeny;
- and
- (f) comparing the data obtained in (e) to identify the components of the pathway.
A method of identifying the molecular components of disease or injury comprising the steps of:
- (a) analyzing the genomic or proteomic makeup of MASC isolated from a healthy donor;
- (b) analyzing the genomic or proteomic makeup of MASC isolated from a donor afflicted with the disease or injury;
- (c) using bioinformatics and/or algorithms to characterize the data from (a);
- (d) using bioinformatics and/or algorithms to characterize the data from (b);
- (e) comparing the data obtained in (c) with that obtained in (d) to identify the molecular components of the disease or injury.
A method of generating products in vitro that have therapeutic, diagnostic or research utility comprising the steps of:
- (a) identifying the products in MASC;
- and
- (b) isolating the products from MASC.
A method of inducing, in a mammal, tolerance to an antigen administered to said mammal, the method comprising the step of administering to said mammal, after or simultaneously with the administration of said antigen, an effective amount of MASC or their progeny so that said mammal's humoral immune response to a subsequent challenge with said antigen is suppressed.
A method for removing toxins from the blood of a patient comprising contacting blood ex vivo with MASC derived cells, wherein said cells line a hollow, fiber based device.
A method for delivering therapeutic products to a patient comprising contacting the blood of said patient ex vivo with MASC or their progeny, wherein said MASC or their progeny are genetically transformed to deliver a therapeutic agent.
A method for testing the toxicity of a drug comprising contacting MASC or their progeny ex vivo with said drug and monitoring cell survival.
Dependencies are inferred from the claim text.